AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase

July 20, 2021 GMT

DURHAM, N.C.--(BUSINESS WIRE)--Jul 20, 2021--

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on Aerie’s globalization outlook at the Ophthalmology Innovation Summit European Innovation Showcase. The slide presentation includes an overview on Aerie’s approach to Europe for both its glaucoma franchise and Aerie’s product candidates.

The slide presentation from today’s event is available now and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com.

ADVERTISEMENT

About Aerie Pharmaceuticals, Inc.

ADVERTISEMENT

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa ® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa ®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa ®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan ® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa ® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan ®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan ®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210720005141/en/

CONTACT: Media: Tad Heitmann 949-526-8747;theitmann@aeriepharma.com

Investors: Ami Bavishi 908-947-3949;abavishi@aeriepharma.com

KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL OPTICAL HEALTH

SOURCE: Aerie Pharmaceuticals, Inc.

Copyright Business Wire 2021.

PUB: 07/20/2021 04:01 PM/DISC: 07/20/2021 04:01 PM

http://www.businesswire.com/news/home/20210720005141/en